HealthcareDEPLOYApproved
India approved the Biovigilance Programme of India for transplant-related safety monitoring
New Delhi, Delhi21 Sept 2026
The central government has approved the Biovigilance Programme of India, under which the Indian Pharmacopoeia Commission (IPC) will lead monitoring and prevention of adverse events linked to medicines and biological products used in organ and tissue transplantation for donors and recipients.
Why it matters
This creates a formal national mechanism to systematically detect and respond to safety risks associated with products used in transplant procedures.
Indian Pharmacopoeia Commission (IPC)Government of India